|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intravenous IgG Therapie: A New Path to Prevent Alzheimer`s Disease?
February 9, 2010
Octapharma USA Announces FDA Approval of wilate® - the First Replacement Therapy Developed Specifically for von Willebrand Disease
January 13, 2010
Octapharma research cooperation further elucidates mechanism of action of octagam
October 30, 2009
Welcome to Octapharma!
Octapharma, a Swiss-based company, is an independent, global plasma fractionation specialist. Its core business is the development, production and sale of high quality human proteins.
The information provided on the Octapharma website is based on world-wide business and approved international product specifications. As registration status and prescribing information for our products vary from country to country, you are encouraged to contact your local Octapharma office for country specific information. In addition, Octapharma is developing specific country web pages which may also be referenced. US residents, for example, should refer to Octapharma USA on the pull down list below for FDA approved product information:
Last update 2/9/2010, © Octapharma AG |
|
 |
|
|
|
